SGHT

Sight Sciences, Inc. NASDAQ

Healthcare ·Medical - Devices ·US · sightsciences.com

$4.22

Mkt Cap $227.9M

52w Low $2.74 22.8% of range 52w High $9.24

50d MA $4.13 200d MA $5.11

P/E (TTM) -6.0x

EV/EBITDA -9.9x

P/B 3.6x

Debt/Equity 0.6x

ROE -60.1%

P/FCF -13.8x

RSI (14) —

ATR (14) —

Beta 2.49

50d MA $4.13

200d MA $5.11

Avg Volume 339.3K

About

Sight Sciences, Inc., an ophthalmic medical device company, engages in the development and commercialization of surgical and nonsurgical technologies for the treatment of eye diseases. The company's products include OMNI Surgical System, a therapeutic device used by ophthalmic surgeons to reduce intraocular pressure in adult glaucoma patients; and TearCare System, a wearable eyelid technology for …

Recent Earnings

Date	Time	Est	Rptd	Surp	Base	Gap%	D1%	D2%	D3%	D4%	D5%	Guide ▲★
Mar 4, 2026	AMC	-0.15	-0.08	+46.7%	5.41	-11.3%	-26.8%	-31.4%	-24.4%	-25.9%	-31.6%	—
Nov 6, 2025	AMC	-0.26	-0.16	+38.5%	5.00	+9.8%	+16.4%	+30.4%	+40.8%	+54.4%	+41.0%	—
Aug 7, 2025	AMC	-0.25	-0.23	+8.0%	3.55	+7.6%	+19.4%	+16.1%	+19.7%	+19.7%	+19.7%	—
May 8, 2025	AMC	-0.29	-0.28	+3.4%	3.03	+11.6%	+1.7%	+5.9%	+12.9%	+8.3%	+12.9%	—
Mar 5, 2025	AMC	-0.22	-0.23	-4.5%	2.42	-7.0%	+2.9%	-2.5%	+1.2%	+15.3%	+11.2%	—
Nov 7, 2024	AMC	-0.23	-0.22	+4.3%	4.68	-4.9%	-9.6%	-1.9%	-9.6%	-15.0%	-17.5%	—
Aug 1, 2024	AMC	-0.31	-0.25	+19.4%	7.42	-4.0%	-15.0%	-25.6%	-26.0%	-25.7%	-21.4%	—
May 2, 2024	AMC	-0.29	-0.33	-13.8%	5.61	+0.0%	+6.2%	+3.7%	+0.7%	-1.1%	-0.9%	—
Mar 7, 2024	AMC	-0.35	-0.22	+37.1%	4.60	+5.0%	+6.1%	-2.8%	-5.0%	-5.0%	-4.1%	—
Nov 7, 2023	AMC	-0.31	-0.27	+12.9%	2.10	-16.7%	-1.9%	-16.4%	-16.4%	-14.0%	-1.9%	—
Aug 3, 2023	AMC	-0.35	-0.30	+14.3%	8.04	+0.6%	+7.6%	+1.1%	+0.9%	-1.7%	-2.5%	—
May 4, 2023	AMC	-0.41	-0.35	+14.6%	10.67	+2.8%	-6.3%	-1.4%	-5.3%	-6.3%	-6.5%	—

Recent Analyst Ratings

Date	Firm	Action	Grade	Target	Base	Open	Gap%	D1%	D2%	D3%	D4%	D5%
Mar 6	UBS	Maintains	Buy → Buy	—	$3.96	$3.80	-4.0%	-6.3%	+3.3%	+1.3%	-6.6%	-8.6%
Mar 6	Citigroup	Maintains	Neutral → Neutral	—	$3.96	$3.80	-4.0%	-6.3%	+3.3%	+1.3%	-6.6%	-8.6%
Mar 2	Stifel	Maintains	Buy → Buy	—	$5.16	$5.19	+0.6%	+8.9%	+1.9%	+4.8%	-23.3%	-28.1%
Jan 5	Piper Sandler	Upgrade	Neutral → Overweight	—	$7.48	$7.95	+6.3%	+3.1%	-0.1%	-0.5%	+0.7%	-4.0%
Dec 23	UBS	Maintains	Buy → Buy	—	$8.44	$8.74	+3.6%	+0.0%	+7.2%	+4.5%	+2.4%	-5.2%
Dec 11	Citigroup	Maintains	Neutral → Neutral	—	$8.46	$8.56	+1.2%	-2.1%	-4.3%	-1.8%	-0.8%	-3.7%
Dec 10	Lake Street	Maintains	Buy → Buy	—	$8.34	$8.44	+1.2%	+1.4%	-0.7%	-2.9%	-0.4%	+0.6%
Dec 2	Morgan Stanley	Maintains	Equal Weight → Equal Weight	—	$8.17	$8.29	+1.5%	+1.6%	+4.8%	+2.1%	-1.5%	+4.4%
Nov 10	Morgan Stanley	Maintains	Equal Weight → Equal Weight	—	$5.82	$5.85	+0.5%	+12.0%	+21.0%	+32.6%	+21.1%	+22.2%
Nov 7	Piper Sandler	Maintains	Neutral → Neutral	—	$5.00	$5.49	+9.8%	+16.4%	+30.4%	+40.8%	+54.4%	+41.0%
Oct 21	Lake Street	Maintains	Buy → Buy	—	$4.66	$4.65	-0.2%	+10.7%	+10.1%	+11.8%	+13.3%	+10.9%
Oct 7	Citigroup	Maintains	Neutral → Neutral	—	$3.36	$3.35	-0.3%	+3.3%	+3.3%	+0.6%	-4.8%	-3.0%
Aug 28	Needham	Maintains	Hold → Hold	—	$4.23	$4.23	+0.0%	-4.5%	-4.0%	-8.5%	-10.2%	-11.8%
Aug 21	Citigroup	Maintains	Neutral → Neutral	—	$4.07	$4.07	+0.0%	+1.2%	+3.9%	+3.4%	+3.9%	+3.9%
Aug 8	Lake Street	Upgrade	Hold → Buy	—	$3.55	$3.82	+7.6%	+19.4%	+16.1%	+19.7%	+19.7%	+19.7%
Jul 15	Morgan Stanley	Maintains	Equal Weight → Equal Weight	—	$3.70	$3.73	+0.8%	-9.7%	-5.1%	-4.3%	-5.4%	-7.3%
Jun 18	Piper Sandler	Maintains	Neutral → Neutral	—	$4.03	$4.02	-0.2%	+6.0%	+0.7%	+7.7%	+5.7%	+4.7%
May 22	Citigroup	Maintains	Neutral → Neutral	—	$3.24	$3.24	+0.0%	+1.2%	-1.2%	+6.2%	+11.4%	+8.6%
May 9	Lake Street	Maintains	Hold → Hold	—	$3.03	$3.38	+11.6%	+1.7%	+5.9%	+12.9%	+8.3%	+12.9%
Apr 9	Needham	Maintains	Hold → Hold	—	$2.09	$2.05	-1.9%	+12.4%	+8.1%	+13.9%	+15.3%	+20.6%
Mar 6	Lake Street	Maintains	Hold → Hold	—	$2.42	$2.25	-7.0%	+2.9%	-2.5%	+1.2%	+15.3%	+11.2%
Mar 6	Needham	Maintains	Hold → Hold	—	$2.42	$2.25	-7.0%	+2.9%	-2.5%	+1.2%	+15.3%	+11.2%
Mar 6	Stifel	Maintains	Buy → Buy	—	$2.42	$2.25	-7.0%	+2.9%	-2.5%	+1.2%	+15.3%	+11.2%
Mar 6	Piper Sandler	Maintains	Neutral → Neutral	—	$2.42	$2.25	-7.0%	+2.9%	-2.5%	+1.2%	+15.3%	+11.2%
Mar 4	Citigroup	Maintains	Neutral → Neutral	—	$2.51	$2.43	-3.2%	-1.6%	-3.6%	-0.8%	-6.0%	-2.4%
Feb 6	Stifel	Maintains	Buy → Buy	—	$2.87	$2.85	-0.7%	-5.6%	-3.5%	-7.0%	-7.3%	-10.8%
Jan 27	UBS	Maintains	Buy → Buy	—	$2.93	$2.89	-1.4%	-0.3%	+6.8%	+4.1%	+1.4%	-4.4%
Jan 15	Lake Street	Maintains	Hold → Hold	—	$3.15	$3.16	+0.3%	-1.3%	-9.8%	-10.2%	-8.3%	-8.6%
Jan 14	Needham	Maintains	Hold → Hold	—	$3.24	$3.24	+0.0%	-2.8%	-4.0%	-12.3%	-12.7%	-10.8%
Dec 11	Citigroup	Maintains	Neutral → Neutral	—	$3.91	$3.95	+1.0%	-0.3%	-4.9%	-8.4%	-6.6%	-7.4%
Nov 11	Morgan Stanley	Maintains	Equal Weight → Equal Weight	—	$4.23	$4.16	-1.7%	+8.5%	+0.0%	-5.9%	-8.7%	-10.2%
Nov 8	Piper Sandler	Maintains	Neutral → Neutral	—	$4.68	$4.45	-4.9%	-9.6%	-1.9%	-9.6%	-15.0%	-17.5%
Jul 15	Morgan Stanley	Maintains	Equal Weight → Equal Weight	—	$7.61	$7.64	+0.4%	+2.8%	+9.2%	+7.2%	+0.7%	+0.0%
Jul 10	Citigroup	Maintains	Neutral → Neutral	—	$6.43	$6.45	+0.3%	-4.4%	+17.0%	+18.4%	+21.6%	+29.2%
May 3	Piper Sandler	Maintains	Neutral → Neutral	—	$5.61	$5.61	+0.0%	+6.2%	+3.7%	+0.7%	-1.1%	-0.9%
Mar 8	Stifel	Maintains	Buy → Buy	—	$4.60	$4.83	+5.0%	+6.1%	-2.8%	-5.0%	-5.0%	-4.1%
Dec 4	Morgan Stanley	Maintains	Equal Weight → Equal Weight	—	$2.90	$3.05	+5.2%	+0.7%	-1.4%	-3.4%	-8.6%	-1.0%
Nov 8	Morgan Stanley	Maintains	Equal Weight → Equal Weight	—	$2.10	$1.75	-16.7%	-1.9%	-16.4%	-16.4%	-14.0%	-1.9%
Sep 18	Stifel	Maintains	Buy → Buy	—	$3.45	$3.40	-1.4%	-2.0%	-10.1%	-16.5%	-14.2%	-11.6%
Sep 15	Citigroup	Maintains	Neutral → Neutral	—	$3.49	$3.48	-0.3%	-1.1%	-3.2%	-11.2%	-17.5%	-15.2%
Sep 13	Morgan Stanley	Maintains	Equal Weight → Equal Weight	—	$3.28	$3.23	-1.5%	+0.6%	+6.4%	+5.2%	+3.0%	-5.5%
Sep 13	BofA Securities	Downgrade	Neutral → Underperform	—	$3.28	$3.23	-1.5%	+0.6%	+6.4%	+5.2%	+3.0%	-5.5%
Sep 12	Piper Sandler	Downgrade	Overweight → Neutral	—	$6.51	$3.81	-41.5%	-49.6%	-49.3%	-46.4%	-47.0%	-48.1%
Sep 12	William Blair	Downgrade	Outperform → Market Perform	—	$6.51	$3.81	-41.5%	-49.6%	-49.3%	-46.4%	-47.0%	-48.1%
Sep 12	BofA Securities	Downgrade	Neutral → Underperform	—	$6.51	$3.81	-41.5%	-49.6%	-49.3%	-46.4%	-47.0%	-48.1%
Aug 24	Morgan Stanley	Downgrade	Overweight → Equal Weight	—	$6.94	$6.52	-6.1%	-9.3%	-8.1%	-8.8%	-1.4%	-5.6%
Aug 21	Citigroup	Maintains	Neutral → Neutral	—	$7.30	$7.17	-1.8%	-1.8%	-3.6%	-4.9%	-13.8%	-12.6%
Aug 4	Morgan Stanley	Maintains	Overweight → Overweight	—	$8.04	$8.09	+0.6%	+7.6%	+1.1%	+0.9%	-1.7%	-2.5%
Jul 11	Citigroup	Downgrade	Buy → Neutral	—	$8.05	$8.04	-0.1%	-6.6%	-5.8%	-3.1%	-3.2%	-9.1%
Jul 10	Citigroup	Downgrade	Buy → Neutral	—	$8.55	$8.04	-6.0%	-5.8%	-12.0%	-11.3%	-8.8%	-8.9%

Recent Filings

8-K · 7.01 ! Medium

Sight Sciences, Inc. -- 8-K 7.01: Regulation FD Disclosure

Sight Sciences lost its patent infringement case against Alcon regarding the Hydrus Microstent, eliminating a potential competitive advantage and removing litigation-related upside for the company.

Apr 23

8-K · 7.01 ! Medium

Unknown — 8-K 7.01: Regulation FD Disclosure

SGHT's core patents face USPTO validity challenges that could weaken its litigation position and competitive moat if claims are ultimately invalidated, despite available appeal options.

Mar 30

8-K · 7.01 ! Medium

Sight Sciences, Inc. -- 8-K 7.01: Regulation FD Disclosure

Sight Sciences disclosed an investor presentation that may be used in upcoming communications with investors and analysts to discuss the company's business and strategy.

Mar 4

8-K · 1.01 !! High

Sight Sciences, Inc. -- 8-K 1.01: Material Agreement

Sight Sciences signed an agreement with Deerfield Campbell, LLC, potentially indicating a strategic partnership or financing arrangement that could impact the company's operational or financial position.

Feb 3

Data updated apr 27, 2026 12:58am · Source: massive.com